ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: Monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression

  • Annick D. Van Den Abbeele
  • , Constantine Gatsonis
  • , Daniel J. De Vries
  • , Yulia Melenevsky
  • , Agnieszka Szot-Barnes
  • , Jeffrey T. Yap
  • , Andrew K. Godwin
  • , Lori Rink
  • , Min Huang
  • , Meridith Blevins
  • , Jo Rean Sicks
  • , Burton Eisenberg
  • , Barry A. Siegel

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Fingerprint

Dive into the research topics of 'ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: Monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression'. Together they form a unique fingerprint.

Medicine and Dentistry